It was announced yesterday by Generex that they have negotiated with a major nationwide pharmacy chain to market the Company's proprietary Crave-NX(TM) 7-Day Diet Aid Spray throughout the pharmacy's nationwide network of over 7,000 stores beginning in January 2010.
The new 7-Day Diet Aid Spray has only 2 Calories and has 20 servings per bottle. This product has been clinically tested to help “Spray the Crave Away ™” while saving calories by controlling the user's sweet tooth and junk food cravings throughout the day, which can save up to 1,000 calories per day.
Commenting on the event Bill Abajian, Sr. Executive Advisor of Global Licensing and Business Development for Generex, stated "The launching of CraveNx(TM) 7-Day Diet Spray with this major pharmacy chain in North America is a significant step forward for Generex as it enters its commercialization phase and a key part of our global marketing strategy. Not only will this make our product widely available to consumers across the U.S., it also adds significant credibility for us as we roll out this brand. We formulated CraveNx(TM) 7-Day Diet Spray to act as a useful tool to combat those late-morning and late afternoon snack cravings that lead to excessive calorie intake as well as obesity and we are fully prepared to support the pharmacy's sales efforts. We have an aggressive media campaign consisting of TV, radio and print ads to create market awareness on the benefits of this product to coincide with the launch."
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
